Amylin receptor 1 (AMY1) (AMY1)

The Amylin receptor 1 (AMY1) is a heterodimeric G protein-coupled receptor (GPCR) formed by the association of the calcitonin receptor (CTR) and the receptor activity-modifying protein 1 (RAMP1) [Source: IUPHAR/BPS Guide to Pharmacology]. As a member of the Class B GPCR family, it is primarily located in the hindbrain's area postrema, where it serves as a key mediator of energy balance and appetite control [Source: PubMed, PMID: 28232024]. Activation of the AMY1 receptor by its endogenous ligand, amylin, results in increased satiety, delayed gastric emptying, and the suppression of glucagon release following meals [Source: Nature Reviews Endocrinology, PMID: 33531691]. These physiological roles make AMY1 a prime therapeutic target for metabolic conditions, particularly obesity and type 2 diabetes. Drugs such as the synthetic amylin analog pramlintide and the long-acting agonist cagrilintide target this receptor to facilitate weight loss and improve glycemic regulation [Source: Clinical Pharmacokinetics, PMID: 34156653]. Furthermore, research suggests AMY1 may play a role in bone metabolism and could offer neuroprotective benefits in the context of Alzheimer's disease [Source: Journal of Alzheimer's Disease, PMID: 28453474].

Other names

CTR/RAMP1 complexCalcitonin receptor-RAMP1 heterodimerAmylin 1 receptor

Agonism of the receptor complex to mimic the effects of endogenous amylin, leading to reduced food intake and improved postprandial glucose levels.